Medicure Reports Widened Q2 Loss and Significant Cash Burn Despite Revenue Growth
MCUJF has more than doubled off its 52-week low of $0.436.
Summary
Medicure reported increased Q2 2026 revenue and positive adjusted EBITDA, but a widened net loss and a substantial decrease in cash due to increased operating cash burn raise significant financial health concerns.
Key Events · Earnings and Guidance · MCUJF
-
Widened Net Loss
Net loss increased to $1.4 million ($0.14/share) in Q2 2026 from $786,000 ($0.08/share) in Q2 2025, partly due to an $864,000 CMS liability.
-
Significant Cash Depletion
Unrestricted cash decreased from $3.8 million at year-end 2025 to $1.8 million by June 30, 2026, a 52% reduction in six months.
-
Increased Operating Cash Burn
Cash used in operating activities for the six months ended June 30, 2026, was $1.4 million, a substantial increase from $73,000 in the prior year period.
-
Revenue Growth & EBITDA Improvement
Total net revenue grew to $7.4 million from $6.7 million year-over-year, and adjusted EBITDA turned positive at $172,000 compared to a negative $28,000 in Q2 2025.
Analysis · MCUJF · Life Sciences
Medicure's Q2 2026 results show revenue growth and improved adjusted EBITDA, but these positives are overshadowed by a significantly widened net loss and a rapid depletion of cash. The company's unrestricted cash balance decreased by over 50% in six months, and operating cash flow turned sharply negative, indicating a high burn rate that raises concerns about its financial runway.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MCUJF was trading at $0.92 on OTC in the Life Sciences sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $0.44 to $1.26. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.